JP2020523315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523315A5 JP2020523315A5 JP2019567574A JP2019567574A JP2020523315A5 JP 2020523315 A5 JP2020523315 A5 JP 2020523315A5 JP 2019567574 A JP2019567574 A JP 2019567574A JP 2019567574 A JP2019567574 A JP 2019567574A JP 2020523315 A5 JP2020523315 A5 JP 2020523315A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound according
- acceptable salt
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004476 heterocycloamino group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- -1 NH 2 Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005122 aminoalkylamino group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- JJRHVVTWSLJCSE-UHFFFAOYSA-N CCN(CC)CCCOc(cc1[nH]c2ccnc(C3CC3)c2c1c1)c1OC Chemical compound CCN(CC)CCCOc(cc1[nH]c2ccnc(C3CC3)c2c1c1)c1OC JJRHVVTWSLJCSE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517410P | 2017-06-09 | 2017-06-09 | |
| US62/517,410 | 2017-06-09 | ||
| PCT/US2018/036521 WO2018226998A1 (en) | 2017-06-09 | 2018-06-07 | Azaindole compounds as histone methyltransferase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523315A JP2020523315A (ja) | 2020-08-06 |
| JP2020523315A5 true JP2020523315A5 (enExample) | 2021-07-26 |
| JP7225125B2 JP7225125B2 (ja) | 2023-02-20 |
Family
ID=62779058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567574A Active JP7225125B2 (ja) | 2017-06-09 | 2018-06-07 | ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11111243B2 (enExample) |
| EP (1) | EP3634962B1 (enExample) |
| JP (1) | JP7225125B2 (enExample) |
| CN (1) | CN110997671A (enExample) |
| AR (1) | AR112192A1 (enExample) |
| BR (1) | BR112019025770A2 (enExample) |
| ES (1) | ES2949402T3 (enExample) |
| IL (1) | IL271066A (enExample) |
| MX (1) | MX2019014759A (enExample) |
| TW (1) | TW201920165A (enExample) |
| WO (1) | WO2018226998A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019014759A (es) * | 2017-06-09 | 2020-02-12 | Global Blood Therapeutics Inc | Compuestos de azaindol como inhibidores de metiltransferasa de histona. |
| JP7749679B2 (ja) * | 2021-02-05 | 2025-10-06 | シンノハブ ファーマシューティカル カンパニー，リミティド | プラスミン阻害剤、その製造方法およびその適用 |
| CN114394971B (zh) * | 2022-01-24 | 2023-01-31 | 云南大学 | 一种吲哚咔唑类化合物的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2402549A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines |
| US20080207632A1 (en) | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
| RU2532135C2 (ru) | 2007-02-22 | 2014-10-27 | Зингента Партисипейшнс Аг | Производные иминопиридина и их применение в качестве микробиоцидов |
| AU2008343932B2 (en) * | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| PL2364983T3 (pl) | 2008-11-11 | 2014-04-30 | Jeil Pharmaceutical Co Ltd | Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna |
| PL2485731T4 (pl) * | 2009-10-06 | 2017-07-31 | Millennium Pharmaceuticals, Inc. | Związki heterocykliczne użyteczne jako inhibitory PDK1 |
| WO2011133795A2 (en) * | 2010-04-22 | 2011-10-27 | The Brigham And Women's Hospital, Inc. | Beta-carbolines as inhibitors of haspin and dyrk kinases |
| US9168247B2 (en) * | 2010-06-25 | 2015-10-27 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
| TW201236880A (en) | 2011-03-11 | 2012-09-16 | Primax Electronics Ltd | Sheet feeding apparatus |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| US9284272B2 (en) | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| DK3154957T3 (da) | 2014-06-16 | 2020-02-17 | Fundacion Para La Investig Medica Aplicada | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
| US10407423B2 (en) | 2015-11-16 | 2019-09-10 | Fundación Para La Investigación Médica Aplicada | Compounds as inhibitors of DNA methyltransferases |
| MX2019014759A (es) * | 2017-06-09 | 2020-02-12 | Global Blood Therapeutics Inc | Compuestos de azaindol como inhibidores de metiltransferasa de histona. |
-
2018
- 2018-06-07 MX MX2019014759A patent/MX2019014759A/es unknown
- 2018-06-07 WO PCT/US2018/036521 patent/WO2018226998A1/en not_active Ceased
- 2018-06-07 JP JP2019567574A patent/JP7225125B2/ja active Active
- 2018-06-07 BR BR112019025770-5A patent/BR112019025770A2/pt not_active Application Discontinuation
- 2018-06-07 EP EP18735073.1A patent/EP3634962B1/en active Active
- 2018-06-07 ES ES18735073T patent/ES2949402T3/es active Active
- 2018-06-07 US US16/002,408 patent/US11111243B2/en active Active
- 2018-06-07 CN CN201880050882.9A patent/CN110997671A/zh active Pending
- 2018-06-08 AR ARP180101557 patent/AR112192A1/es unknown
- 2018-06-08 TW TW107119935A patent/TW201920165A/zh unknown
-
2019
- 2019-12-01 IL IL271066A patent/IL271066A/en unknown
-
2021
- 2021-08-06 US US17/396,312 patent/US20210371417A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529324A5 (enExample) | ||
| PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| MX2020011294A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina. | |
| JP2019505541A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2014518882A5 (enExample) | ||
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| JP2014531449A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2015001571A (es) | Compuestos de anillo en puente como inhibidores del virus de la hepatitis c (hcv) y sus aplicaciones farmaceuticas. | |
| WO2004074270A3 (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
| JP2016506961A5 (enExample) | ||
| IL274229B1 (en) | Antibacterial compounds | |
| JP2019526596A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| RU2016141405A (ru) | (5,6-дигидро)пиримидо[4,5-е]индолизины | |
| JP2020500866A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| MX2009006593A (es) | Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4. | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |